MTORC1 and Sirolimus: A link with fertility;MTORC1 et sirolimus: Un lien avec la fertilité

Medecine/Sciences

Volumn 29, Issue 2, 2013, Pages 200-205

  Tartarin, Pauline ^a   Froment, Pascal ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; MULTIPROTEIN COMPLEX; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 1;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; BRAIN; DRUG EFFECT; FEMALE; FERTILITY; GENETICS; GONAD; HUMAN; MALE; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIFUNGAL AGENTS; BRAIN; FEMALE; FERTILITY; GONADS; HUMANS; MALE; MODELS, BIOLOGICAL; MULTIPROTEIN COMPLEXES; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84874749004     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/2013292019     Document Type: Article

References (35)

1. Dutcher JP. Mammalian target of rapamycin inhibition. Clin Cancer Res 2004; 10 : 6382S-7S.
2. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991; 253 : 905-9.
3. Sabatini DM, Erdjument-Bromage H, Lui M, et al. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994; 78 : 35-43.
4. Murakami M, Ichisaka T, Maeda M, et al. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol 2004; 24 : 6710-8.
5. Guertin DA, Stevens DM, Thoreen CC, et al. Ablation in mice of the mTORC components raptor, rictor or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCa, but not S6K1. Dev Cell 2006; 11 : 859-71.
6. Monget P. Régulation endocrine et paracrine de la folliculogenèse. Med Sci (Paris) 1999; 15 : 141-7.
7. Froment P, Holzenberger M, Monget P. Insuline, métabolisme énergétique et fertilité Med Sci (Paris) 2001; 17 : 817-8.
8. Froment P, Gizard F, Staels B, et al. Un rôle pour PPARγ dans la reproduction ? Med Sci (Paris) 2005; 21 : 507-11.
9. Tosca L, Chabrolle C, Dupont J. L'AMPK : un lien entre métabolisme et reproduction ? Med Sci (Paris) 2008; 24 : 297-300.
10. Zuber J, Anglicheau D, Elie C, et al. Sirolimus may reduce fertility in male renal transplant recipients. Am J Transplant 2008; 8 : 1471-9.
11. Gill JS, Zalunardo N, Rose C, et al. The pregnancy rate and live birth rate in kidney transplant recipients. Am J Transplant 2009; 9 : 1541-9.
12. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22 : 159-68.
13. Huyghe E, Zairi A, Nohra J, et al. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. Transpl Int 2007; 20 : 305-11.
14. Bererhi L, Flamant M, Martinez F, et al. Rapamycin-induced oligospermia. Transplantation 2003; 76 : 885-6.
15. Skrypek J, Krause W. Azoospermia in a renal transplant recipient during sirolimus (rapamycin) treatment. Andrologia 2007; 39 : 198-9.
16. Feng LX, Ravindranath N, Dym M. Stem cell factor/c-kit Up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3 kinase/p70 S6 kinase pathway in spermatogonia. J Biol Chem 2000; 275 : 25572-6.
17. Musnier A, Leon K, Morales J, et al. mRNA-selective translation induced by FSH in primary Sertoli cells. Mol Endocrinol 2012; 26 : 669-80.
18. Fumel B, Sow A, Fouchécourt S, et al. Une nouvelle fonction pour la transferrine exprimée par le testicule. Andrologie (Paris) 2009; 19 : 81-9.
19. Li WR, Chen L, Chang ZJ, et al. Autophagic deficiency is related to steroidogenic decline in aged rat Leydig cells. Asian J Andro 2011; 13 : 881-8.
20. Cure P, Pileggi A, Froud T, et al. Alterations of the female reproductive system in recipients of islet grafts. Transplantation 2004; 78 : 1576-81.
21. Braun M, Young J, Reiner CS, et al. Ovarian toxicity from sirolimus. N Engl J Med 2012; 366 : 1062- 4.
22. Kayampilly PP, Menon KM. Follicle-stimulating hormone increases tuberin phosphorylation and mammalian target of rapamycin signaling through an extracellular signal-regulated kinasedependent pathway in rat granulosa cells. Endocrinology 2007; 148 : 3950-7.
23. Palaniappan M, Menon KM. Human chorionic gonadotropin stimulates theca-interstitial cell proliferation and cell cycle regulatory proteins by a cAMP-dependent activation of Akt/mTORC1 signaling pathway. Mol Endocrinol 2010; 24 : 1782-93.
24. Yu J, Yaba A, Kasiman C, et al. mTOR controls ovarian follicle growth by regulating granulosa cell proliferation. PLoS One 2011; 6 : e21415.
25. McLaughlin M, Patrizio P, Kayisli U, et al. mTOR kinase inhibition results in oocyte loss characterized by empty follicles in human ovarian cortical strips cultured in vitro. Fertil Steril 2011; 96 : 1154-9.
26. Alam H, Maizels ET, Park Y et al. Follicle-stimulating hormone activation of hypoxia-inducible factor 1 by phosphatidylinositol 3 kinase/Akt/Ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation. J Biol Chem 2004; 279 : 19431-40.
27. Shivaswamy V, Ochsner L, Maroni D, et al. Tacrolimus and sirolimus induce reproductive abnormalities in female rats. Transplantation 2011; 91 : 1333-9.
28. Mabuchi S, Altomare DA, Connolly DC, et al. RAD001 (everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 2007; 67 : 2408-13.
29. Maira SM, Stauffer F, Brueggen J, et al. Identification and development of NVP-BEZ235, a new orally available dual PI3K/mTOR inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7 : 1851-63.
30. Roa J, Garcia-Galiano D, Varela L, et al. The mammalian target of rapamycin as novel central regulator of puberty onset via modulation of hypothalamic Kiss1 system. Endocrinology 2009; 150 : 5016-26.
31. Julien LA, Roux PP. mTOR, la cible fonctionnelle de la rapamycine. Med Sci (Paris) 2010; 26 : 1056-60.
32. Pallet N, Beaune P, Thervet E, et al. Inhibiteurs de mTOR : Des antiprolifératifs pléiotropiques. Med Sci (Paris) 2006; 22 : 947-52.
33. Le Bacquer O, Martineau Y, Mamane Y. Quand la traduction sort de sa TORpeur. Med Sci (Paris) 2006; 22 : 514-18.
34. Greenland C, Delsol G, Payrastre B. La kinase FRAP/mTOR : une nouvelle cible dans le traitement des cancers dépendants de la voie PI3-kinase/PTEN. Med Sci (Paris) 2002; 18 : 137-9.
35. Joly D. Inhibition thérapeutique de mTOR dans la polykystose rénale autosomique dominante. Med Sci (Paris) 2011; 27 : 249-51.